

Sydney, Australia. 1 March, 2018.

PHEBRA WELCOMES PBS LISTING OF BENZATROPINE INJECTION

Pharmaceutical manufacturer Phebra is pleased that its Australian made Benztropine Injection (benztropine mesilate) is now accessible via the Pharmaceutical Benefits Scheme (PBS).

The Federal Government has listed the drug on the PBS, effective 1 March, 2018.

Phebra's Chief Executive Officer, Dr Mal Eutick, welcomed the decision, saying Benztropine Injection had proven to be an effective treatment for all forms of Parkinsonism, as well as drug-induced disorders.

"Benztropine Injection is a powerful anticholinergic agent which can improve the lives of people suffering the debilitating effects of Parkinson's disease and other neurological disorders," Dr Eutick said today.

"The drug is mainly effective in relieving tremor and rigidity, allowing the patient to have more normal body movements, with minimum discomfort."

"It is effective at any stage of the disease, even when a patient becomes bedridden and is helpful in patients who have become unresponsive to other drugs."

Phebra is producing Benztropine Injection at its manufacturing plant at Lane Cove West in Sydney.

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

Phebra media contact: Richard Lenarduzzi. 0411 254 390